Tumor mutational burden and response rate to PD-1 inhibition

New England Journal of Medicine

Volumn 377, Issue 25, 2017, Pages 2500-2501

  Yarchoan, Mark ^a   Hopkins, Alexander ^a   Jaffee, Elizabeth M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

BASAL CELL CARCINOMA; CANCER GENETICS; CLINICAL OUTCOME; COLORECTAL CANCER; DISEASE BURDEN; HUMAN; LETTER; LUNG CARCINOMA; MALIGNANT NEOPLASM; MISMATCH REPAIR; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SARCOMATOID CARCINOMA; SOMATIC MUTATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DNA MUTATIONAL ANALYSIS; GENETICS; MUTATION; NEOPLASM;

ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85039783649     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1713444     Document Type: Letter

References (5)

1. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
2. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20.
3. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-13.
4. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9: 34.
5. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374: 2542-52.